All brokerage houses barring Motilal Oswal highlighted in this article are having Reduce to Hold rating and expect the stock to fall up to 25 percent.
As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
Revenue during the quarter is seen declining 17 percent to Rs 6,861 crore compared with Rs 8,265 crore in same quarter last fiscal, according to average of estimates of analysts polled by CNBC-TV18.
Net Sales are expected to decrease by 15.2 percent Y-o-Y (up 12.8 percent Q-o-Q) to Rs. 7006.1 crore, according to Kotak.
In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.
Operating profit is likely to crash 40 percent to Rs 1,744.5 crore and margin may contract 1,080 basis points to 24.6 percent compared with same quarter last year.
Net Sales are expected to decrease by 2.39 percent Q-o-Q (down 16.79 percent Y-o-Y) to Rs 6662 crore, according to KR Choksey. Sun Pharma to report net profit at 1713.2 crore down 24.69% year-on-year.
Net Sales are expected to decrease by 5.9 percent Q-o-Q (down 2.4 percent Y-o-Y) to Rs 7449.4 crore, according to ICICI Securities. Sun Pharma to report net profit at 1458.4 crore down 0.9% quarter-on-quarter.
Most analysts noted that the Q3 results were below their estimates, but maintained their buy rating on the stock revising the target price slightly on lower side on hopes of Halol resolution, US specialty play kicking in and normalisation of India business.
According to average of estimates of analysts polled by CNBC-TV18, revenue during the quarter may increase 11.6 percent year-on-year to Rs 7,905.3 crore, driven by Sun's authorised generic (AG) launches of Daichi Sankyo drugs in US.
The company said it plans to mitigate the any loss in revenue from Glumetza and Fortamet with over 25 potential launches in the next 12 months - including some big ones such as as birth-control pill Minastrin 24, HIV drug Epzicom, hepatitis-B medication viread, among others.
Surajit Pal, Research Analyst at Prabhudas Lilladher, said the pharma sector is undergoing a transition and all the large midcaps will underperform.
Net Sales are expected to decrease by 2.4 percent Q-o-Q (up 9.8 percent Y-o-Y) to Rs 7773.7 crore, according to ICICI Securities.
Net Sales are expected to decrease by 3 percent Q-o-Q (up 6.9 percent Y-o-Y) to Rs 7529.4 crore, according to KR Choksey.
Healthcare major Sun Pharmaceutical Industries' Profit more than doubled to Rs 2,235.1 crore in the quarter ended September 2016 compared with Rs 1,028.8 crore in year-ago period, driven by overall healthy business performance.
Healthcare major Sun Pharmaceutical Industries' second quarter profit is seen rising 52.3 percent year-on-year to Rs 1,685 crore on strong operational performance.
Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 8.3 percent Y-o-Y) to Rs 7407 crore, according to Centrum.
Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.
Most analysts think business in India has most likely improved in the last three month but there may be challenges this quarter when it comes to recovery in sectors like capital goods, construction and engineering.
Surajit Pal of Prabhudas Lilladher talks about Sun Pharma and Glenmark's June quarter earnings.
According to a CNBC-TV18 poll, the drug major is likely to see revenue growth of 20.2 percent at Rs 7876.6 crore in Q1 against Rs 6552.2 crore in year-ago period.
A number of large companies have posted results since the earnings season started Thursday last week.
Sales are expected to increase by 5.2 percent Q-o-Q (up 18.8 percent Y-o-Y) to Rs 8029.8 crore, according to Religare Research.
Net Sales are expected to increase by 9.3 percent Q-o-Q (up 19.9 percent Y-o-Y) to Rs 8106.7 crore, according to Edelweiss
In an interview with CNBC-TV18, Pankaj Pandey of ICICI Direct talked about the brokerage's expectations from the first quarter earnings season and outlined his view on various sectors.